Citadel Advisors LLC Reports 9.99% Ownership in Spruce Biosciences, Inc.

Citadel Advisors LLC, along with its affiliates, has reported a 9.99% ownership in Spruce Biosciences, Inc. through a Schedule 13G filing with the SEC. The filing indicates that Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin each beneficially own 109,649 shares of Spruce Biosciences' common stock. The shares are held by Citadel CEMF Investments Ltd., with Citadel Advisors acting as the portfolio manager. The filing also notes that the shares were not acquired for the purpose of influencing the control of the issuer. The effective date of the filing is October 16, 2025.